A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

NCT03672175 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

581

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: SAGE-217
DRUG: Placebo

Sponsor

Biogen